Imatinib Amarox

Imatinib, the active ingredient in Imatinib Amarox, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing disease‑modifying benefit in several hematologic and solid‑tumor indications. - Chronic Myeloid Leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and prolongs progression‑free survival. - Philadelphia‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): contributes to remission induction and maintenance therapy.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the extremities, especially ankles. - Fatigue: persistent tiredness not relieved by rest. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function such as shortness of breath. - Severe bleeding: unusual bruising or hemorrhage. - Pulmonary hypertension: elevated pressure in lung arteries. - Interstitial lung disease: inflammation of lung tissue causing cough and dyspnea.

Before initiating therapy, clinicians should assess baseline health status and monitor for potential complications. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: periodic LFTs are recommended. - Evaluate cardiac status: watch for signs of heart failure. - Avoid use in patients with known hypersensitivity to imatinib. - Pregnancy: risk unknown; discuss benefits and risks with a physician. - Store at below 25°C: keep in the original pack, protect from moisture and light.

Imatinib's metabolism and absorption can be altered by concomitant medicines, requiring careful review.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure and toxicity. - CYP3A4 inducers (e.g., rifampin): may lower plasma levels and reduce efficacy. - Antacids containing aluminum or magnesium: can decrease oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may raise INR; monitor coagulation parameters. - Loop diuretics (e.g., furosemide): may exacerbate fluid retention. - Live vaccines: reduced effectiveness; consider timing of vaccination.